Ovid Therapeutics appoints Stelios Papadopoulos to Board of Directors

Ovid Therapeutics Inc.

Board expanded from five to six directors; Papadopoulos appointed Class I director, term through 2027 annual meeting.
Papadopoulos co-founded Exelixis, served as Chairman of Biogen (2014-2023), and has extensive biotech investment banking background.
Appointed to Audit Committee and Compensation Committee, effective March 1, 2025.
Non-employee director compensation updated: $45,000 base retainer, initial 90,000 stock options grant, annual 45,000 options.
Entered standard indemnification agreement covering expenses for actions arising from director service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stelios Papadopoulos

Class I director

OVID · Ovid Therapeutics Inc.

Effective: 2025-03-01
Filed: March 5, 2025, 6:59 PM ET

On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stelios Papadopoulos was appointed as Class I director at Ovid Therapeutics Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company

View on SEC.gov

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-047174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.